Overview

Dose-Ranging Study to Assess the Safety, PK and Initial Antiviral Efficacy of NVR 3-778 in Chronic HBV Patients

Status:
Completed
Trial end date:
2016-05-18
Target enrollment:
0
Participant gender:
All
Summary
This Phase 1b trial will assess the dose-related safety and PK profile of different doses of NVR 3-778 in patients with chronic hepatitis B. Additionally,changes in patients' serum HBV DNA levels and other virologic efficacy parameters will be assessed.
Phase:
Phase 1
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Novira Therapeutics, Inc.
Treatments:
Antiviral Agents
Interferon-alpha
Peginterferon alfa-2a
Criteria
Patients may be male or female between 18 and 65 years of age, with a BMI of 18-35kg/m2.
Patients must be HBeAg positive and have chronic hepatitis B with no history of clinical
decompensation.